Merck & Co. news

While Merck has a favorable average brokerage recommendation of 1.67 (Buy-equivalent with 62.1% Strong Buy ratings), the article advises caution. The company's unchanged consensus earnings estimate of $2.97 for the current year resulted in a Zacks Rank #3 (Hold), suggesting the stock should perform in line with the broader market in the near term rather than outperform.

Stock has risen 39.5% year-to-date with strong revenue growth driven by blockbuster Keytruda expected to maintain strong sales through 2028. Company has expanded pipeline with 20 planned drug launches by 2030, recent positive phase III data for personalized cancer therapy with Moderna, and strategic acquisitions to prepare for post-Keytruda period. Assigned Zacks Rank #3 (Hold), making it the preferred choice over AstraZeneca.

Merck's phase III pipeline has nearly tripled since 2021 with 20 new drug launches expected by 2030. The company has $70 billion in potential pipeline opportunity by mid-2030s, more than double Keytruda's peak sales. Newer products like Winrevair, Capvaxive, and Welireg are showing strong growth, positioning the company well for the post-Keytruda era.

Outperformed industry with +29.1% gain over six months. Blockbuster Keytruda and new products drive sales, Animal Health contributes to growth, and M&A deals strengthen pipeline. However, Keytruda patent loss in 2028 and recent estimate declines due to M&A costs present headwinds.

Merck demonstrates strong near-term growth drivers with Keytruda momentum and positive clinical data, but faces significant long-term challenges from Keytruda's 2028 patent expiration, declining Gardasil sales, and generic competition. The stock is rated Hold with valuation above historical averages, reflecting balanced risk-reward.

Mixed results with earnings beat and revenue growth offset by significantly lowered full-year EPS guidance due to acquisition charges, downward estimate revisions, and Hold rating. Stock gained 18.2% post-earnings but faces headwinds from moderating Keytruda growth and margin pressures.

Stock rose 1% and hit all-time high; combined treatment addresses critical patent cliff on Keytruda in 2028 by creating new revenue opportunity; larger, more diversified company reduces risk compared to Moderna

Merck is mentioned only in the context of its 2025 acquisition of Verona Pharma, which is historical background information about the newly appointed board member. There is no direct news or developments regarding Merck itself.

Merck is mentioned only as the owner of the branded Januvia and Janumet drugs that generated $4.5 billion in combined global sales in 2022. DIABIT-IS X is a generic alternative that will compete in this market, but the article does not provide specific competitive impact analysis.

FDA approval for label expansion of Capvaxive to a new patient population (at-risk children and teens) represents market expansion and competitive advantage as the only vaccine specifically studied and indicated for this group. However, stock was down 2.95% at time of publication, suggesting market may have already priced in expectations or had other concerns.

While the lung cancer trial discontinuation is disappointing, the positive HIV regimen results provide a counterbalance. The stock was up 0.46% at publication, suggesting the market viewed the outcomes as relatively balanced with slight positive tilt from the HIV trial success.

Merck is partnering with Erasca and providing pembrolizumab at no cost for the AURORAS-1 trial, demonstrating confidence in the combination's potential. This collaboration expands the clinical utility of KEYTRUDA® in RAS-driven cancers, a large patient population (~2.7 million diagnosed annually), which could represent a significant commercial opportunity.

Merck is mentioned only as a reference point for InVitria's product validation through ERVEBO® vaccine use. No direct news or developments regarding Merck are discussed in the article.

Mixed results with a quarterly loss driven by acquisition charges, but beat earnings expectations and raised full-year guidance. Strong growth in oncology and animal health offset by vaccine segment weakness. Technical indicators show short-term weakness with bearish MACD momentum.

Listed as a key competitor with exposure to pharmaceutical and biotechnology end-use segments that require strict filtration and contamination control measures.

Merck is highlighted as a leading company expanding its oncology portfolio with targeted therapies and immunotherapies for vulvar cancer treatment, positioning it well for market growth.

Stock fell 4.08% due to Phase 3 trial failure to meet primary endpoints for advanced RCC treatment. However, sentiment is partially offset by FDA approval of new HIV treatment Idvynso and potential alternative treatment pathways identified by analysts.

Merck is recognized as a solid dividend stock with strong fundamentals, including Keytruda as the world's best-selling cancer drug, promising pipeline candidates like CD388, and a robust dividend program with 93.8% growth over the past decade. However, it faces near-term headwinds from declining Gardasil sales and upcoming Keytruda patent expiration.

Merck's decision to lower its acquisition offer by $8 per share (13% reduction) based on disappointing trial data suggests weakened confidence in the asset's value and commercial potential, despite maintaining interest in the deal.

Stock declined 3.12% due to broader market downturn and sector weakness, but fundamentals remain supported by strong 12-month performance (+44.67%), bullish MACD signals, and strategic growth opportunity from Terns acquisition. Buy rating with $122.22 price target suggests underlying strength despite near-term headwinds.

Merck demonstrated strong strategic execution through a $6.7B acquisition of Terns Pharmaceutical, expanding its oncology pipeline. The company shows robust financial health with consistent earnings beats (19 of 20 quarters), 14 consecutive years of dividend increases, high gross margins (73%), and analyst consensus of Moderate Buy with 7% upside potential. Strong institutional ownership and minimal short interest further support positive outlook.

Merck secured exclusive rights to develop antibody candidates through a strategic collaboration with Infinimmune, strengthening its pipeline and offsetting revenue risks from Keytruda patent concerns. The stock showed positive movement in premarket trading and is near its 52-week high.

Identified as a dominant market leader with substantial participation in pioneering advances in esophageal cancer treatment.

Merck is actively acquiring assets to address pipeline pressure from Keytruda's upcoming patent expiration, demonstrating strategic growth initiatives. Stock price up 2.23% at announcement.

Merck is strategically expanding its hematology and oncology pipeline with the acquisition of a promising clinical-stage asset (TERN-701) that has shown encouraging early clinical results. The deal strengthens Merck's position in oncology and diversifies its portfolio with a potentially best-in-class candidate for CML treatment.

Merck is proactively addressing future revenue challenges by acquiring promising oncology assets. The acquisition strengthens its pipeline ahead of Keytruda's patent expiration in 2028, demonstrating strategic foresight and commitment to maintaining growth.

Merck is expanding its immunology pipeline through a novel collaboration that could provide unique biological insights into IBD, potentially leading to more effective therapeutic options for a disease affecting millions globally with no current disease-modifying treatments available.

Merck is identified as a leading company at the forefront of the growing Zostavax market, which is experiencing significant growth due to demographic factors, increased healthcare spending on preventive care, and expanded vaccine access. The company is well-positioned to benefit from these market tailwinds.

Merck is identified as a major company in the RotaTeq market, which is experiencing notable growth driven by expanding immunization initiatives, rising rotavirus prevalence, and increased healthcare spending. The market is forecast to expand through 2030-2035, positioning Merck favorably in this growing segment.

Expanded partnership with Tempus to leverage advanced AI and data analytics for precision medicine development, particularly in oncology. This strategic move enhances Merck's capabilities in identifying novel biomarkers and cancer resistance mechanisms, supporting its therapeutic portfolios.

Identified as a prominent MXene market player with exposure to high-growth 2D materials sector experiencing 35.6% CAGR through 2032.

FDA approval for expanded use of Keytruda in a new indication (pretreated ovarian cancer) with strong clinical trial results showing significant improvements in progression-free and overall survival. The drug continues to show strong sales growth ($8.37B in Q4 2025, +7% YoY), indicating market demand and revenue expansion potential.

Mentioned as a competitor to Eli Lilly in the pharmaceutical space, but no detailed analysis provided in the article.

Merck has a notably positive ESP of +3.91%, indicating a meaningful gap between the Most Accurate Estimate ($2.34) and Zacks Consensus Estimate ($2.25). This suggests a higher probability of beating earnings expectations based on recent analyst revisions.

Merck's Keytruda combined with Moderna's intismeran showed statistically significant and clinically meaningful improvements in melanoma treatment outcomes. The partnership represents a promising growth opportunity that could bring in billions in revenue for the company.

Listed as a top holding (4.91%) in SCHD but no specific analysis or commentary provided about the company itself.

Listed as the top holding in SCHD (4.91% allocation), indicating it is a high-quality dividend-paying stock favored by the fund's strategy.

Included as a comparable mega-cap pharmaceutical peer for valuation benchmarking.

Mentioned only as a valuation comparison point. No direct news impact.

Co-developer of successful intismeran autogene therapy showing positive Phase III results; expanding oncology portfolio through partnership; evaluating combination therapy across multiple tumor types with strong clinical data.

Merck's Keytruda is being evaluated in combination with Kimmtrak in the TEBE-AM study. While Keytruda remains a strong revenue driver ($16.4B in H1 2026), the article provides no specific positive or negative developments regarding Merck itself.

Featured company with significant presence in immunotherapy, particularly in checkpoint inhibitors and cancer indications, positioned to benefit from market expansion.

Merck is listed as a panel participant discussing AI implementation and workforce transformation in clinical operations but no specific company details or outcomes are mentioned.

Merck is identified as a key competitor to GSK in both HIV and oncology markets, suggesting it has competitive products capturing market share in these high-growth therapeutic areas.

Major key player positioned to benefit from expanding monoclonal antibody market driven by cancer and autoimmune disease treatment demand.

Listed as a top holding (4.88%) of SCHD, indicating it meets the ETF's rigorous dividend criteria and represents a solid, cash-flow-heavy company with a proven track record.

Third-largest holding in IHE at 5%. Included as a major pharmaceutical position but no specific sentiment or analysis provided.

Merck successfully acquired Terns Pharmaceuticals and added TERN-701 to its oncology pipeline, which received FDA Breakthrough Therapy Designation, strengthening its CML treatment portfolio.

Merck is mentioned only as a former employer of the appointed director. No direct business developments, partnerships, or impacts to Merck are discussed in the article.

Mentioned as a competitor with Capvaxive vaccine in the same Phase 3 trial comparison. No direct news impact on Merck; mentioned only as a competitive benchmark.

Tulisokibart met primary endpoints in Phase 3 ATLAS-UC trial, demonstrating clinical remission superiority over placebo with consistent safety profile, strengthening Merck's position in the growing UC market.

Listed as major key player in the expanding AI pharmaceutical market